A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Latest Information Update: 23 Jul 2024
At a glance
- Drugs SI B001 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
- 27 Jun 2024 Planned End Date changed from 1 Apr 2024 to 1 Aug 2024.
- 27 Jun 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Aug 2024.
- 30 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Apr 2024.